vosoritide
Peptideexperimental
Clinical trial activity
9 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
7
Phase 3
2
Phase 4
0
Earliest trial started Feb 1, 2012 (NCT01590446)
Timeline
Indications
Mechanism of action
- Atrial natriuretic peptide receptor CSupplementation
NPR3 supplementation
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- bmn 111
- bmn 111
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05845749 | Phase 1/Phase 2 (Phase 2) | Sep 25, 2023 | University of California, San Francisco |
| NCT05813314 | Phase 1 | Mar 15, 2023 | Biomarin |
| NCT03989947 | Phase 2 | Jun 12, 2019 | Biomarin |
| NCT03583697 | Phase 2 | May 23, 2018 | Biomarin |
| NCT03424018 | Phase 3 | Dec 12, 2017 | Biomarin |
| NCT03197766 | Phase 3 | Dec 12, 2016 | Biomarin |
| NCT02724228 | Phase 2 | Jan 1, 2016 | Biomarin |
| NCT02055157 | Phase 2 | Jan 1, 2014 | Biomarin |
| NCT01590446 | Phase 1 | Feb 1, 2012 | Biomarin |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biomarin | For profit | 8 | 8 | 3 | 2012 |
| University of California, San Francisco | Academic/Hospital | 1 | 1 | 1 | 2023 |
2 organizations
Page 1 / 1